It\u27s Not Just  Skin Deep : Social Anxiety and Anxiety Sensitivity in Adults with Psychodermatological Disorders by Ellison, Lauren E.
University of Mississippi
eGrove
Honors Theses Honors College (Sally McDonnell BarksdaleHonors College)
2019
It's Not Just "Skin Deep": Social Anxiety and
Anxiety Sensitivity in Adults with
Psychodermatological Disorders
Lauren E. Ellison
University of Mississippi
Follow this and additional works at: https://egrove.olemiss.edu/hon_thesis
Part of the Psychology Commons
This Undergraduate Thesis is brought to you for free and open access by the Honors College (Sally McDonnell Barksdale Honors College) at eGrove. It
has been accepted for inclusion in Honors Theses by an authorized administrator of eGrove. For more information, please contact egrove@olemiss.edu.
Recommended Citation
Ellison, Lauren E., "It's Not Just "Skin Deep": Social Anxiety and Anxiety Sensitivity in Adults with Psychodermatological Disorders"
(2019). Honors Theses. 1089.
https://egrove.olemiss.edu/hon_thesis/1089
  
 
 
 
IT’S NOT JUST “SKIN DEEP”: SOCIAL ANXIETY AND ANXIETY SENSITIVITY 
IN ADULTS WITH PSYCHODERMALOGICAL DISORDERS 
 
 
 
 
By  
Lauren Ellison  
 
 
A thesis submitted to the faculty of the University of Mississippi in partial fulfillment of 
requirements for the Sally McDonnell Barksdale Honors College 
 
 
Oxford  
May 2019 
 
 
 
 
 
          Approved by:  
 
Advisor: Professor Laura J. Dixon  
 
Reader: Dean Lee M. Cohen  
 
  
 
ii 
 Reader: Professor John N. Young  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
iii 
© 2019 
Lauren Elizabeth Ellison  
ALL RIGHTS RESERVED 
 
ACKNOWLEDGEMENTS 
 I would like to begin by thanking my advisor, Dr. Laura J. Dixon, and my mentor, 
Sara Witcraft, for their invaluable support and guidance on this project. They both 
devoted countless hours to editing drafts, answering questions, and encouraging me 
throughout the thesis writing process. They are both incredible role models and I 
absolutely could not have completed my thesis without their help. 
 In addition, I would like to thank my second and third readers, Dr. John N. Young 
and Dean Lee M. Cohen, for taking the time to read over my drafts and provide feedback. 
I would also like to thank the faculty, staff, and students of the Sally McDonnell 
Barksdale Honors College. The hoco has been one of the most integral parts of my 
college experience, and the faculty members and my fellow students have helped me 
grow and mature in ways that I never could have foreseen.  
I would also like to thank my friends for encouraging me throughout the writing 
process; thank you for believing in me and pushing me to be the best that I can be. Last, 
but certainly not least, I would like to thank my parents for their unwavering support in 
all of my endeavors. I would not be where I am today without you.  
 
 
 
 
 
  
 
iv 
 
 
 
Abstract 
Anxiety contributes to dermatological conditions and, due to the visible nature of skin 
conditions, social anxiety is particularly salient to dermatology patients. Although many 
dermatology outpatients report clinically significant social anxiety symptoms, there is 
little understanding of social anxiety among dermatology patients. Anxiety sensitivity 
(AS), or the fear of the consequences of anxiety, has been implicated in both social 
anxiety and dermatological symptoms. To this end, this study aimed to further elucidate 
the relation of social anxiety and AS among skin disease in two separate samples of 
individuals with psychodermatological conditions. We hypothesized that AS social, but 
not physical or cognitive, concerns would emerge as a unique predictor of social anxiety 
symptoms after accounting for covariates. Study 1 consisted of 164 participants (Mage = 
31.88; 69.5% female; 83.5% White) with active skin conditions who were recruited 
through Amazon’s Mechanical Turk. Study 2 included 63 patients (Mage = 51.49; 70.7% 
female; 65% White) who were recruited from an outpatient dermatology clinic. In both 
samples, AS social concerns emerged as a unique factor contributing to social anxiety. 
The findings suggest heightened concerns about the negative consequences related to 
their visible skin condition may worsen social anxiety symptoms. Future research should 
examine the efficacy of brief AS interventions that target fears of social consequences in 
individuals with psychodermatological disorders. 
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 It’s Not Just “Skin Deep”: Social Anxiety and Anxiety Sensitivity in Adults with 
Psychodermatological Disorders  
 Research has shown that psychological disorders are especially common in 
dermatology patients, with an estimated prevalence ranging from 25% to 40% (Aktan, 
Ozmen, & Sanli, 1998; Hughes, Barraclough, Hamblin, & White, 1983; Niemeier et al., 
2002; Picardi et al., 2000; Rasoulian, Ebrahimi, Zare & Taherifar, 2010; Wessely & 
Lewis 1989), compared to the 17.6% rate of occurrence observed in the general 
population (Kessler et al., 2012). The high rate of comorbidity of psychological and 
dermatological disorders has contributed to the formation of psychodermatology for 
disease classification, representing the intersection between psychiatry and dermatology. 
Psychodermatological disorders represent skin conditions affected by psychological 
stress, meaning that the psychological factors play a modulating role in the etiology, 
course, and prognosis of these disorders (Buske-Kirschbaum & Hellhammer, 2006; 
Griesemer, 1978; Jafferaney, 2007, Verhoeven et al., 2009). Psychodermatological 
disorders include disorders such as acne, atopic dermatitis (eczema), psoriasis, rosacea, 
urticaria (hives), vitiligo, and seborrheic dermatitis (Koo & Lebwohl, 2001).  
 Psychodermatological disorders have been classified into three categories: 
psychophysiologic disorders, primary psychiatric disorders, and secondary psychiatric 
disorders (Koo & Lee, 2003). Regarding psychophysiologic disorders, the skin disease 
(e.g., acne, eczema) may be either precipitated or exacerbated by psychological factors 
such as stress or anxiety, though the disease itself is not directly caused by psychological 
changes. In primary psychiatric disorders, psychopathology contributes to the 
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manifestation of skin symptoms. Examples include delusions of parasitosis, 
trichotillomania, and skin picking from obsessive compulsive disorders. Lastly, 
secondary psychiatric disorders consist of dermatologic disorders with psychiatric 
symptoms, such as alopecia aerate and psoriasis. Individuals with secondary psychiatric 
disorders typically experience anxiety, depression, and other emotional difficulties 
because of their skin disease. 
 Although only formally acknowledged in recent years, the bi-directional 
relationship between the mind and the skin has long been hypothesized (Sneddon, 1949). 
Indeed, the two are intertwined from the very beginnings of embryological development, 
with the developing brain and the skin sharing several receptors, neurotransmitters, and 
hormones (Rasoulian, Ebrahimi, Zare & Taherifar 2010). The immune system, in 
particular, plays a key regulatory role in the interaction between skin and psyche. 
Emotional factors (e.g., stress) can precipitate changes in the immune system and 
produce dermatological symptoms, such as acne breakouts and urticaria flares, by way of 
histamine release and increased vasodilation (Jeremy, Holland, Roberts, Thomson & 
Cunliffe, 2003; Misery, 1996; Teshima et al., 1986). This immunomodulated 
inflammatory response can subsequently affect the symptomatology of dermatological 
disorders by inflaming the epithelial and endothelial cells of the skin (Buske-Kirschbaum, 
Gierens, Hollig & Hellhammer, 2002).   
 Psoriasis can be used to exemplify the interaction between skin and psychological 
symptoms. For instance, one study found that 39% of psoriasis patients reported a 
significant stressful event within one month prior to the first episode of the disease 
(Seville, 1977). Likewise, Gaston and colleagues (1987) examined the relationship 
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between stress and psoriasis prospectively over the course of twenty weeks. The results 
indicated a positive correlation between the severity of psoriasis symptoms and the 
ongoing experience of psychologic distress and adverse life events. Although stress and 
other psychological factors have been shown to precipitate changes in the skin (Gupta, 
Gupta & Watteel, 1997; Ganceviciene, Graziene, Fimmel & Zouboulis, 2009; Morren et 
al., 1994; Tsukahara et al., 2003; Wygledowska-Kania, Bogdanowski & Polska, 1996), 
there is also evidence that dermatology patients may be more vulnerable to psychological 
syndromes. Multiple studies have indicated that psychological symptoms are common 
among dermatology patients (Dalgard et al., 2015; Gascòn et al., 2012; Picardi et al., 
2000; Sheehan-Dare et al., 1990; Woodruff et al., 1997). For example, patients with 
moderate to severe acne vulgaris often report elevated levels of depression, anxiety, and 
suicidal ideation (Purvis, Robinson, Merry, & Watson 2006; Yazici et al., 2004). 
Likewise, Ahmed and colleagues (2007) found that patients with vitiligo had significantly 
higher rates of depression and anxiety than healthy controls. A population-based cohort 
study conducted by Olivier and colleagues (2010) looked at anxiety, depression, and 
suicidality in 149,998 psoriasis patients and 766,950 patients without psoriasis. As 
expected, patients with psoriasis showed an increased risk for all three diagnoses. 
Collectively, the above studies are indicative of the complex interaction between the 
mind and skin, and as such, call for further examination of dermatological conditions and 
co-occurring psychological factors.     
 Anxiety and depression are some of the most pervasive psychiatric disorders among 
dermatology patients, with estimated prevalence rates of 17% and 20%, respectively 
(Picardi et al., 2006). In particular, anxiety can have significant implications for skin 
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diseases. For instance, anxiety disorders are associated with increases in stress responses, 
and thus lead to heightened cortisol levels and inflammation (Evers, 2010). Importantly, 
both high cortisol levels and inflammation can directly affect the onset, progression, and 
resolution of dermatological disorders (Teshima et al., 1986; Wessely & Lewis 1989). 
The estimated prevalence of anxiety disorders among dermatology patients is on the 
order of 24 – 35% in outpatient clinics (Picardi et al., 2004; Woodruff, Higgens, Du 
Vivier & Wesseley, 1997), although moderate to severe anxiety symptoms are discernible 
in 52 – 77% of dermatology patients (Gascon et al., 2012, Rasoulian et al., 2010). Indeed, 
77% of dermatology outpatients reported moderate to severe anxiety symptoms, 
compared to only 26% reported by healthy controls (Rasoulian et al., 2010). Taken 
together, anxiety and dermatological disorders appear to be highly comorbid.  
 Social anxiety disorder (SAD; previously known as social phobia) has been found 
to be one of the most pervasive anxiety disorders, affecting 7.4% of the U.S population 
each year (Kessler et al., 2012). According to the 5th edition of the Diagnostic and 
Statistical Manual of Mental Disorders (DSM-5), the first of the diagnostic criteria for 
SAD is “marked fear or anxiety about one or more social situations in which the 
individual is exposed to possible scrutiny by others, including social interactions, being 
observed, and performing in front of others” (American Psychiatric Association [APA], 
2013). Individuals with SAD exhibit a hypersensitivity to criticism, negative evaluation, 
and rejection, stemming from low self-esteem and recurrent feelings of inferiority (APA, 
2013; Cox, Fleet & Stein, 2004; Stopa & Clark, 1993). Individuals with SAD often have 
inaccurate perceptions of themselves, especially in social situations when they allocate 
important attentional resources to monitoring their actions and the reactions of those 
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around them (Rapee & Lim, 1992; Stopa & Clark, 1993). Flushing, trembling, 
stammering, heart palpitations, and sweating are some of the hallmark physical indicators 
of this disorder (APA, 2013). Despite the significant impairments associated with SAD, 
only about half of individuals with the disorder ever seek treatment, and typically do so 
after ten or more years of suffering (Wang et al., 2005).  
 Several negative outcomes are closely associated with SAD. First, the overall 
quality of life for those suffering from SAD is often reduced (Schneider, 2006). General 
impairments, which can range from performance anxiety to complete social isolation, can 
result in diminished emotional and social functioning (Mennin, McLaughlin & Flanagan, 
2009; Stein, Walker & Forde 1996). Individuals with SAD are much less likely to marry 
than those who do not have the disorder and, for those who do marry, the decreased 
occupational and interpersonal functioning can cause exceptional tension and strain on 
the marriage (Salzer & Schallreuter, 2015). Work and school productivity can be 
significantly impaired as well, as indicated by a threefold higher rate of unemployment 
among individuals with the disorder (Wittchen & Beloch, 1996). Compared to those 
without SAD, individuals with SAD report significantly more impairments in work and 
school performance (Fehm, Beesdo, Jacobi & Fiedler, 2007) and are of lower 
socioeconomic status than those without the disorder (Schneier et al. 1992). In addition to 
the various negative outcomes of SAD, the disorder is also associated with a variety of 
comorbid psychiatric conditions that can worsen disability and prognosis (Lepine & 
Pelissolo, 1993). SAD is frequently comorbid with major depressive disorder and other 
anxiety disorders, such as panic disorder, agoraphobia, and obsessive-compulsive 
disorder (Schneier, Johnson & Hornig, 1992). Relative to skin disease, the negative 
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outcomes of SAD may be particularly problematic due to the highly visible nature of 
these conditions.   
 Dermatological disorders and SAD are highly co-morbid, with approximately 33 – 
46% of dermatology outpatients reporting clinically significant social anxiety symptoms 
(Bez, Yesilova, Kaya & Sir, 2011; Montgomery et al., 2016; Yarpuz, Saadet, Sanli & 
Ozguven, 2008). Many dermatology patients fear that the prominence of their disease 
may attract attention (or perceived attention) in social situations (Jowett & Ryan, 1985). 
Further, social anxiety symptoms may worsen dermatological symptoms, further 
exposing individuals to visible symptoms which might further amplify fears of scrutiny 
(Dixon and Witcraft, 2018). Unfortunately, SAD symptoms tend to worsen prognosis in 
dermatological patients (Salman, Kurt, Topcuoglu & Demircay, 2016; Schneider et al., 
2013).  
 The connection between SAD and dermatological disorders has been examined in 
several studies. Salman and colleagues (2016) found that vitiligo and acne patients who 
exhibited social anxiety symptoms experienced greater impairments than those without 
social anxiety symptoms. Schneider and colleagues (2013) found a similar trend in 
psoriasis patients, as those with social anxiety symptoms experienced significantly 
greater psychological distress than those without social anxiety symptoms. Likewise, 
Lessa and colleagues (2014) found that patients with both hyperhidrosis and social 
anxiety symptoms experienced greater disability and a more impaired quality of life than 
those with hyperhidrosis symptoms alone. Despite the fact that social anxiety symptoms 
are associated with worse wellbeing of individuals with dermatological disorders, the 
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empirical literature in this area is remarkably limited, and few studies have sought to 
investigate the mechanisms by which they are related.  
 Anxiety sensitivity is thought to play a broad role in the development and 
maintenance of anxiety disorders, including SAD (Naragon-Gainey, 2010; Olatunji & 
Wolitzky-Taylor, 2009), and may precede the onset of anxiety disorders rather than 
occurring as a consequence of the anxiety itself (Donnell & McNally, 1989, Reiss & 
McNally, 1985; Taylor et al., 1992). Anxiety sensitivity (AS) is defined as the propensity 
to fear the cognitive, physical, and social consequences of anxiety symptoms, such as 
embarrassment, social rejection, insanity, illness, or even death (Reiss & McNally, 1980; 
Taylor et al. 2007). AS is posited to be an anxiety amplifier, meaning that anxious 
individuals often become alarmed about their symptoms, which subsequently intensifies 
their anxiety (Taylor, Koch & McNally, 1992). For instance, an individual with SAD 
might notice that s/he becomes flushed during an interview, causing his/her heart rate to 
increase, which worsens flushing. Additionally, AS also plays a role in social anxiety 
with co-occurring dermatological symptoms, as the association between social anxiety 
and impairment due to skin disease has been shown to be mediated by AS (Dixon, 
Witcraft, & Perry, 2019). 
 AS is comprised of three, empirically established factors: cognitive concerns, 
physical concerns, and social concerns (Taylor et al., 2007). Individuals with elevated 
cognitive concerns generally fear that their anxiety symptoms will lead to some form of 
mental incapacitation, such as insanity. The physical concerns facet is associated with an 
increased sensitivity to the physiological cues of anxiety, such as heart palpitations and 
increased heart rate, with individuals interpreting the physiological symptoms as leading 
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to catastrophes such as cardiac arrest or stroke. Finally, the social concerns facet is 
associated with the belief that publicly observable anxiety reactions, such as flushing and 
trembling, will elicit ridicule and social rejection (Taylor et al., 2007). Deacon and 
Abramowitz (2006) found that the social facets of AS were particularly elevated among 
individuals with SAD. Patients with SAD differed markedly from participants with other 
anxiety disorders in regard to AS, with social phobics fearing anxiety-related sensations 
due to the potential for negative social evaluation, not concerns about physical or 
cognitive catastrophes. Given the high rates of co-morbidity between SAD and 
dermatological disorders and the highly visible nature of skin disease, AS social concerns 
may be an especially important vulnerability factor for individuals with 
psychodermatological disorders.   
 Prior work suggests that the social facets of AS may play a more important 
regulatory role in the development and maintenance of dermatological disorders than the 
cognitive and physical concerns facets. For instance, Dixon and colleagues (2016) found 
that patients with psychodermatological disorders demonstrated significantly elevated AS 
when compared to patients with nonpsychodermatological disorders, but the social 
concerns facets of AS had the most robust association with psychodermatological 
disorders after adjusting for general anxiety symptoms. Additional research has shown 
that stress is associated with skin disease quality of life among adults with active skin 
disease at high, but not low, levels of AS social concerns (Dixon, Witcraft, McCowan, & 
Brodell, 2018).  
 This preliminary research suggests that the social facets of AS are a unique 
contributor to the symptoms of psychodermatological disorders, specifically SAD. 
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However, the underlying mechanisms by which the two are linked have yet to be 
examined, and additional research is needed to further extrapolate the role of the different 
facets of AS in dermatological patients. A more in depth understanding of the 
mechanisms that connect the skin and psyche could result in more efficacious treatment 
plans and potentially alleviate both psychological and dermatological symptoms. To this 
end, the aim of this project is to examine associations between AS facets in relation to 
social anxiety symptoms, specifically among individuals with psychodermatological 
disorders in two separate samples: 1) an online sample of adults with active skin 
conditions and 2) a treatment-seeking sample of dermatology patients. We hypothesized 
that the AS social concerns will demonstrate a stronger association with social anxiety 
symptoms as compared to the physical and cognitive concerns facets. Additionally, we 
hypothesized that AS social concerns will account for more variance in social anxiety 
symptoms than AS cognitive or physical concerns, after accounting for theoretically 
relevant variables including age (Kessler et al., 2005), sex (Turk et al.,1998), and anxiety 
(Schneier et al.,1992). We expected that these findings would be observed in the 
nonclinical sample and replicated in the patient sample. 
 
 
 
 
 
 
 
  
 
10 
 
 
 
 
 
 
 
 
 
STUDY 1 
Method 
Participants and Procedure 
 Participants were recruited through Amazon’s Mechanical Turk using 
TurkPrime.com, an online crowdsourcing software that compensates “workers” for 
completing tasks (Litman, Robinson, & Abberbock, 2017). To be eligible for the current 
study, workers must have been located in the United States, been 18 years or older, and 
completed a minimum of 100 tasks with at least an 85% approval rating. After providing 
consent, eligible workers (N =1,129) completed a health screen questionnaire to 
determine eligibility for the study. Individuals reporting past-year dermatological 
symptoms (n = 357) were invited to participate in the second portion of the study. After 
consenting to study procedures, eligible participants completed a series of questionnaires 
Participants were compensated $3.50 for study procedures. The study protocol was 
approved by the University of Mississippi’s Institutional Review Board.  
  
 
11 
 Data was collected from 237 participants (67.9% female; Mage = 34.18, SDage = 
9.574) who consented to the study and reported current dermatological symptoms. 
Participants were excluded from the current study if they did not report the presence of a 
current psychodermatological condition. In accordance with the previous literature 
(Dixon et al., 2016; Jafferany 2007), dermatological conditions were categorized as either 
“nonpsychodermatological” and “psychodermatological.” While “psychodermatology” 
refers to disorders which may be triggered or exacerbated by psychological factors (e.g., 
acne, psoriasis, atopic dermatitis), “nonpsychodermatology” refers to skin conditions 
which are solely precipitated by biological factors (e.g., skin cancer, skin lesions). 
Participants who reported both nonpsychodermatological and psychodermatological 
conditions were classified as “psychodermatological” because it was surmised that 
participants with psychodermatological disorders would report higher levels of AS 
regardless of co-occurring nonpsychodermatological disorders. Additionally, primary 
psychiatric disorders and secondary psychiatric disorders were excluded from the final 
sample, due to the fact that these disorders tend to be psychological in origin (Koo & 
Lebwohl, 2001). The following psychodermatological disorders were reported and 
included in the final sample: acne, atopic dermatitis, rosacea, psoriasis, seborrheic 
dermatitis, perioral dermatitis, hyperhidrosis, hives, dermatitis, ichthyosis, vitiligo, 
alopecia, and factitial dermatitis. Nonpsychodermatological issues that were excluded 
from the final sample included skin cancer, moles, scarring, in-grown toenails, keloids, 
fungal infections, wrinkles, warts, shingles, melasmas, skin tags, birthmarks, hair loss, 
lesions, rashes, trichotillomania, and body dysmorphic disorder.    
Measures   
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 Anxiety Sensitivity Index- 3 (ASI-3). The ASI-3 (Taylor et al., 2007) includes 18 
items designed to measure both the frequency and severity of the physical (“when I feel 
pain in my chest, I worry that I’m going to have a heart attack”), cognitive (“when my 
thoughts seem to speed up, I worry that I might be going crazy”), and social (“I worry 
that other people will notice my anxiety”) facets of AS. Participants are asked to indicate 
the extent to which they agree with each statement on a 5-point Likert scale, which 
ranges from 0 (“very little”) to 4 (“very much”).  Total scores can range from 0 to 72, 
with higher scores indicating worse AS. Individuals obtaining a score of 23 or above are 
classified as having clinically significant levels of AS (Allen et al., 2014). The ASI-3 has 
demonstrated excellent overall internal consistency (Cronbach’s ⍺ = .93) in both clinical 
and undergraduate student samples (Wheaton, Deacon, McGrath, Berman, & 
Abramowitz, 2012). Additionally, the ASI-3 demonstrated good convergent and 
divergent validity in that the subscales were highly correlated with similar subscales of 
the original Anxiety Sensitivity Index and evidenced smaller correlations with dissimilar 
subscales (Taylor et al., 2007). In the current study, the ASI-3 demonstrated excellent 
internal consistency for the cognitive subscale (cog = .93) and great internal consistency 
for the social and physical subscales (⍺soc= .86; phy = .89). See Appendix A. 
 Social Phobia Inventory (SPIN). The SPIN (Connor et al., 2000) is a 17-item, 
self-report scale from 0 (“not at all”) to 4 (“extremely”). Items assess the severity of the 
physiological symptoms (e.g., distressed by palpitations), avoidance (e.g., avoids 
speeches), and fear (e.g., fear of talking to strangers) associated with social phobia (social 
anxiety disorder). The items are summed to produce a total score, which ranges from 0 to 
68, with higher scores corresponding to more severe social phobia symptoms. The 
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recommended clinical cut-off of 19 discriminates between those with and without social 
phobia (Connor et al., 2000). Regarding psychometric properties, the SPIN has 
demonstrated excellent internal consistency in both clinical samples ( = .91) and 
undergraduate samples ( = .94) (Carleton et al., 2010), and adequate test-retest 
reliability (Connor et al., 2000). Lastly, the SPIN demonstrated excellent internal 
consistency in the present study (Cronbach’s  = .96) See Appendix B.  
 Depression, Anxiety, & Stress Scales – 21 (DASS-21). The DASS-21 (Lovibond 
& Lovibond, 1995) is a 21-item self-report questionnaire that assesses depression, 
anxiety, and stress symptoms. Total scores range from 0 to 84, with higher scores 
corresponding with more severe symptoms. Lovibond and colleagues (1995) found that 
the DASS-21 successfully discriminates between depression, anxiety, and stress, despite 
the fact that these syndromes are still highly correlated with one another. The anxiety 
subscale (e.g., “I had feelings of shakiness”) measures physiological symptoms of anxiety 
whereas the stress subscale (e.g., “I found it difficult to relax”) measures cognitive 
symptoms of anxiety (Lovibond & Lovibond, 1995). The current study used only the 7-
item Anxiety subscale. The DASS-21-Anxiety scale has been found to have excellent 
overall internal consistency (Cronbach’s  = .93) in both clinical and undergraduate 
samples (Lovibond & Lovibond, 1995; Osman et al., 2012). The DASS-21-Anxiety 
subscale has evidenced good convergent and discriminant validity when compared to 
other validated measures of anxiety (Henry & Crawford, 2005). In the present study, the 
DASS-21-Anxiety demonstrated excellent internal consistency (Cronbach’s  = .95). See 
Appendix C. 
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 Demographics and Dermatological Information Form. Participants reported 
sociodemographic characteristics, including age, sex, employment status, and education 
level. In addition, participants responded to a checklist of dermatological conditions 
experienced in the last four weeks (i.e., currently). See Appendix D.  
Results Study 1 
Participant Characteristics  
 Data were cleaned and examined. Per the aforementioned inclusion criteria for 
psychodermatological disorders, 164 participants were included in the study and 73 
participants were excluded. The overall sample was primarily female (69.5%) and was an 
average age of 31.88 years (SD = 8.05). The sociodemographic characteristics in this 
subsample were similar to those observed in the full sample. The majority of participants 
were White (83.5%). Other ethnicities represented in the sample included Black/African 
American (9.1%), Asian/Southeast Asian (6.1%), American Indian (1.2%), and 6.7% 
Latin. The majority of participants had education beyond high school (87.2%) and most 
were employed either part time (16.5%) or full time (56.7%).    
 The most frequently reported psychodermatological disorder was acne (82.3%) 
followed by atopic dermatitis (32.9%) and dermatitis (15.2%; see Table 1) Additionally, 
60.7% of participants reported clinically significant levels of social anxiety symptoms (M 
= 28.33, SD = 18.80) and 45.1% reported clinically elevated levels of AS (M = 25.52, SD 
= 16.58; see Table 1 for AS subscale scores).    
Bivariate Correlations 
 Pearson correlations were utilized to test the hypothesis that the AS social concerns 
would demonstrate a stronger association with social anxiety symptoms than the physical 
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and cognitive concerns facets. As expected, AS social concerns demonstrated the highest 
correlation (r = .71) with social anxiety, when compared to the physical (r = .54) and 
cognitive (r = .56) concerns of AS (all p’s < 0.01). See Table 1.   
Multiple Linear Regression 
 A multiple linear regression was computed to test the hypothesis that AS social 
concerns would account for greater variance in social anxiety symptoms than AS 
cognitive or physical concerns, over and above theoretically-relevant variables. In Step 1, 
age, sex, and anxiety were entered as the predictors, and accounted for 34.6% of the 
variance in social anxiety symptoms, F (3,160) = 29.46, p < .001. In Step 2, the physical, 
cognitive, and social facets of AS were entered into the model, which accounted for an 
additional 20.8% of the variance in social anxiety symptoms, ∆F (6, 157) = 24.96, p 
<.001. Consistent with the hypothesis, AS social concerns, but not physical or cognitive 
concerns, emerged as a unique predictor of social anxiety. See Table 3. 
 
STUDY 2 
Method 
Participants and Procedure 
 Patients seeking outpatient dermatology care were recruited through the University 
of Mississippi Medical Center (UMMC) Dermatology Clinics. Following patient check-
in, UMMC Dermatology Clinic personnel introduced patients to the research study and 
distributed a questionnaire packet including demographics, ASI-3, DASS-21, and SPIN 
(see Study 1 for measure information). Written consent was waived by the IRB for this 
study, and patients were informed in a cover letter that returning a completed measure 
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packet was indicative of their consent to be a part of the study. In addition, patients were 
informed that their participation (or lack thereof) would not affect their treatment, and no 
compensation was provided for their participation. Interested patients returned their 
anonymous questionnaire packets to clinic personnel. The study protocol was approved 
by the University of Mississippi’s Institutional Review Board.   
 Inclusion and Exclusion Criteria. To be eligible for the study, the patients had to 
be 18 years or older and English speaking. This study used the same criteria as Study 1 to 
identify between participants with psychodermatological disorders. That is, participants 
who reported non-psychodermatological disorders, such as skin cancer, were excluded 
from this study.  
Measures  
 Anxiety Sensitivity Index- 3 (ASI-3).  See study 1 for the psychometric properties 
of ASI-3. In Study 2, the internal consistency ranged from great to excellent for all three 
subscales (⍺soc= .86; cog = .93; phy = .89).  
 Social Phobia Inventory (SPIN). See Study 1 for the psychometric properties of 
SPIN. In Study 2, the internal consistency was adequate ( = .76). 
 Depression, Anxiety, & Stress Scales – 21 (DASS-21). See Study 1 for the 
psychometric properties of the DASS-21. In Study 2, the internal consistency was great 
( = .89).  
 Demographics Form. This form was utilized to obtain general medical and 
demographic information. The questionnaire included items assessing age, sex, 
marital/relationship status, ethnicity, education, total family/household income, and 
employment status. In addition, patients identified their current dermatological issues or 
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diagnoses by circling common disorders and/or responding to a free-response item. See 
Appendix E.  
Results 
Participant Characteristics 
 The data were cleaned and participants who did not complete measures pertinent to 
the current study were excluded from analyses. Using the previously described inclusion 
criteria, 60 participants were excluded from the current study and the final sample was 
comprised of 63 participants with psychodermatology disorders. The final sample was 
primarily female (81%), and was on average 47.94 years old (SD = 16.05). Participants 
identified as White (58.7%), Black/African American (39.7%), and Native American 
(1.6%). Additionally, most individuals had education beyond high school (73.0%), were 
employed (52.4%), and married (50.8%). The most common psychodermatological 
disorder was acne (31.8%), followed by atopic dermatitis (30.1%) and psoriasis (27%). 
Overall, 27.2% of patients reported social anxiety levels of clinical significance (M = 
15.65, SD = 14.69) and 35.2 % of participants reported clinically significant levels of AS 
(M = 21.03, SD = 16.76; see Table 1 for AS subscale scores).     
Bivariate Correlations 
 Pearson correlations revealed that that among psychodermatology patients, the 
correlation between the social facets of AS social anxiety symptoms was large (r = .75) 
whereas medium-sized correlations were observed between social anxiety symptoms and 
AS physical (r = .49) and cognitive facets (r = .56; all ps <.01). See Table 1. 
Multiple Linear Regression 
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  In Step 1, age, sex, and anxiety were entered as the predictors, and accounted for 
34.1% of the variance in social anxiety symptoms F (3,55) = 10.004, p < .001. In Step 2, 
the physical, cognitive, and social facets of AS were entered into the model, which 
accounted for an additional 26.6% of the variance in social anxiety symptoms, ∆F (3, 55) 
= 12.421, p <.001. Supporting the hypothesis, AS social concerns, but not physical or 
cognitive concerns, emerged as a unique predictor of social anxiety. See Table 4. 
 
 
 
 
 
 
 
 
 
 
Discussion 
 The current study examined the physical, cognitive, and social facets of AS in 
relation to social anxiety symptoms in two samples of adults with psychodermatological 
disorders. In both samples, AS social concerns emerged as a unique factor contributing to 
social anxiety symptoms, above the theoretically-relevant covariates of age, sex, and trait 
anxiety. These findings suggest heightened concerns about the negative social 
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consequences related to their visible skin condition may exacerbate social anxiety 
symptoms among individuals with psychodermatological disorders. 
 Participants in both studies demonstrated elevated levels of social anxiety, with 
60.7% and 27.2% of individuals reporting clinically significant levels of social anxiety in 
the online and patient samples, respectively. These results are consistent with those of 
prior studies which have shown high rates of comorbidity between SAD and 
dermatological disorders (Bez, Yesilova, Kaya & Sir, 2011; Montgomery et al., 2016; 
Yarpuz, Saadet, Sanli & Ozguven, 2008). Interestingly, participants in Study 1 
demonstrated significantly elevated social phobia levels when compared to the 
participants in Study 2. This disparity could be attributed to a variety of factors, such as 
differences in demographics and sample size. For instance, the sample in Study 1 (N = 
164) was larger than that of Study 2 (N = 62), and a larger sample size minimizes the 
effects of statistical outliers. Further, participants in Study 1 were on average 16 years 
younger than those in Study 2, which is consistent with previous research which finds 
that social anxiety is more prevalent among younger samples (Cairney et al., 2007; Flint 
et al., 2010; Kessler et al., 2005; Regier et al., 1988). Anxiety disorders, such as SAD, 
have a peak age of onset in early adulthood and their incidence and prevalence decline 
later in life (Kessler et al., 2005), and individuals may become more adept at managing 
their social anxiety with age (Henderson, Form, Korten & Jacomb, 1998). Individuals 
who report highly visible dermatological symptoms tend to report significantly elevated 
levels of social anxiety, which could explain the comparably high levels of social anxiety 
in Study 1 (Montgomery, Norman, Messenger & Thompson, 2016; Salman, Kurt, 
Topcuoglu & Demicray, 2016). In Study 1, the majority of participants reported acne as 
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their chief dermatological complaint (82.3%), whereas participants in Study 2 reported 
notably lower rates of acne (31.8%), and a higher frequency of psoriasis (Study 1: 8.5% 
vs. Study 2: 27%). Research suggests that SAD may be prevalent in as many as 45.7% of 
acne patients (Bez, Yesilova, Kaya & Sir, 2011), though SAD prevalence rates appear to 
be as low as 4% among individuals with disorders such as psoriasis (Golpour et al., 
2012). Acne symptoms are typically localized to highly visible areas of the body (e.g., 
face, upper back, chest), whereas psoriasis and eczema may present to more concealable 
areas of the body (e.g., Shalita, 2004).  
 Consistent with expectations, although the three facets of AS were positively 
correlated with social anxiety symptoms, the social concerns facets demonstrated the 
strongest association with social anxiety symptoms in both samples. These findings 
support the premise that individuals with psychodermatological disorders may experience 
elevated concerns about the social consequences of physiological arousal due to the 
visible nature of skin disease (e.g., sweating). Further, as these samples, on average, 
experienced elevated levels of social anxiety symptoms, it stands to reason that they may 
also experience concerns about the physical and cognitive consequences related to 
anxiety. 
 As hypothesized, the social facets of AS emerged as a unique predictor of social 
anxiety symptoms in both psychodermatological samples. These results are consistent 
studies implicating the social facets of AS in the etiology and maintenance of SAD 
(Olthius, Watt & Stewart, 2014). Although previous literature has established age 
(Kessler et al., 2005), gender (Asher & Aderka; 2018), and anxiety (Schneier et al.,1992) 
as significant risk factors for SAD, the current study suggests that the social facets of AS 
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play a more salient role in social anxiety among psychodermatological conditions. Adults 
with skin disease may fear that their anxiety-related symptoms and the visibility of their 
dermatological symptoms will result in negative consequences, such as ridicule, social 
rejection, negative evaluation, and worsened dermatological symptomatology (i.e., acne 
breakout or psoriasis flare). These fears may result in greater distress and psychosocial 
impairment, which could further exacerbate skin symptoms.  
 Although this study replicated and extended current knowledge of the 
psychodermatology literature, several limitations warrant consideration. First, the 
methodology of the first study relied on an online crowdsourcing platform. Although 
attention check questions were used to exclude careless responders and to improve 
validity (Meade & Craig, 2012), participants could have answered questionnaires 
dishonestly or carelessly, and dermatological symptoms were not verified by a clinician. 
These limitations were partially addressed in Study 2, which used an in-person sample of 
patients presenting to a dermatology clinic and paper-pencil questionnaires. Second, the 
cross-sectional design of both studies precludes temporal or causal associations. 
Longitudinal studies are needed to better understand the development of 
psychodermatological disorders, social anxiety symptoms, and the social facets of AS 
over time and to identify additional risk factors. Third, social anxiety symptoms were 
assessed via self-report, rather than clinical interview. Future studies should seek to 
replicate the findings of Study 1 and Study 2 in a clinical sample of individuals diagnosed 
with SAD. Additionally, both samples lacked gender diversity, as the majority of 
participants were female (Study 1 = 69.5%; Study 2 = 81.0%). Although the sample 
limits the generalizability of the findings, females account for approximately 60% of 
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dermatology visits (Stern 2004) and have higher lifetime prevalence rates of SAD 
compared to men (Weinstock, 1999; Xu et al., 2012). Therefore, the results may represent 
a majority of patients presenting to dermatology clinics with social concerns. Next, high 
correlations between AS facets in Study 2 indicates potential for multicollinearity, such 
that one of the facets may be suppressed in accounting for variance in the outcome. 
Lastly, dermatological disorders in Study 1 and Study 2 were dichotomized as either 
psychodermatological or nonpsychodermatological and not examined on an individual 
basis. Subsequent research should target specific psychodermatological and 
nonpsychodermatological disorders to look for variance, or lack thereof, in social anxiety 
symptoms and social AS among individuals with different disorders.   
 Psychological interventions appear to be useful adjuncts to conventional 
dermatological treatments for individuals with psychodermatological disorders, and 
improving the specificity of such treatments by targeting the social facets of AS could 
potentially streamline intervention processes and maximize effectiveness (Hedman-
Lagerlof, Bergman, Lindefors & Bradley, 2018; Shenefelt, 2000; Smits, Berry, Tart & 
Powers, 2008; Woodruff, Higgens, Du Vivier & Wessely, 1997). Interventions such as 
cognitive-behavioral therapy, which work by altering the dysfunctional thought patterns 
or actions that are associated with anxiety symptoms, have been shown to effectively 
reduce AS (Capron & Schmidt, 2016; Kneough & Schmidt, 2012; Olthuis, Watt, 
MacKinnon & Stewart, 2014). In the future, dermatologists and other clinicians may use 
assessments of AS social concerns to screen for at risk individuals and provide brief AS 
interventions targeting social concerns related to their skin and anxiety symptoms. 
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Clinicians could also refer at-risk patients to psychology specialists or therapists for 
further psychological evaluation and treatment.   
 In summary, psychodermatology is relatively new area of research, and the 
literature within this discipline is remarkably limited. This study is one of the few of its 
kind to examine SAD among individuals with psychodermatological disorders, and the 
findings regarding the social facets of AS have further elucidated the mechanisms by 
which the mind and skin are related.  Moreover, this study provides a replication, 
demonstrating that the social facets of AS appear to be a unique contributor to social 
anxiety symptoms in both clinical and nonclinical samples.  
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Table 1. Psychodermatological disorders 
 Study 1 (N = 164) Study 2 (N = 63) 
 % (n) % (n) 
Acne 82.3 (135) 31.8 (20) 
Eczema (Atopic Dermatitis) 32.9 (53) 30.1(19) 
Psoriasis 8.5 (14) 27 (17) 
Dermatitis  15.2 (25) 3.2 (2) 
Seborrheic Dermatitis  11.0 (18) 0.0  
Factitial Dermatitis  1.8 (3) 0.0 
Rosacea   6.7 (11) 6.4 (4) 
Urticaria (hives)  3.0 (5) 0.0 
Alopecia Areata  1.2 (2) 4.8 (3) 
Vitiligo  0.6 (1) 1.6 (1) 
Ichthyosis  0.6 (1) 0.0 
Prurigo Nodularis  0.0 1.6 (1) 
Hyperhidrosis  3.0 (5) 1.6 (1) 
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Table 2. Means, Standard Deviations, and Correlations between Study Variables 
 Study 1 Study 2 1. 2. 3. 4. 5. 
 M (SD) M (SD)      
1. Anxiety 10.69 (9.82) 7.98 (10.76) - .57** .52** .66** .59** 
2. Social Anxiety 28.32 (7.88) 15.65 (14.69) .59** - .48** .56** .747** 
3. AS Physical 7.88 (6.42) 7.63 (6.28) .65** .54** - .79** .71** 
4. AS Cognitive 5.92 (6.57) 5.48 (6.01) .65** .55** .65** - .74** 
5. AS Social 11.71 (6.30) 7.98 (6.19) .567** .71** .61** .57** - 
Note. M = mean; SD = standard deviation. Anxiety= DASS-21 Anxiety; Social Anxiety= 
Social Phobia Inventory total; AS Physical, AS Cognitive & AS Social = three subscales of the 
ASI-3. Values below the diagonal of the correlation matrix are from the MTurk sample; values 
above the diagonal are from the patient sample. 
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Table 3. Multiple linear regression of anxiety sensitivity facets in social anxiety 
symptoms among MTurk workers (N = 164) 
 R2 B SE(B) p 
Step 1  .356   <.001 
   Age   -.074 .153 .628 
   Sex   -1.785 2.375 .453 
   Anxiety  1.129 .125 <.001 
Step 2 .208   <001 
   Age   -.142 .128 .270 
Sex  .020 1.993 .992 
Anxiety  .396 .152 .010 
AS Physical  .048 .232 .838 
    AS Cognitive  .327 .221 .140 
  AS Social   1.519 .212 <.001 
Note. AS = Anxiety sensitivity; anxiety= DASS-21 Anxiety; social anxiety = Social 
Phobia Inventory total; AS Physical, AS Cognitive & AS Social = three subscales of the 
ASI-3. 
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Table 4. Multiple linear regression of anxiety sensitivity facets in social anxiety 
symptoms among psychodermatology patients (N = 63) 
 R2 B SE(B) p 
Step 1  .341   <.001 
   Age   0.062 -.068 .548 
   Sex   .580 .016 .889 
   Anxiety  .777 .571 <.001 
Step 2 .266   <001 
   Age   .023 .083 .781 
Sex  -1.341 3.312 .687 
Anxiety  .316 .161 .054 
AS Physical  -.407 .339 .325 
    AS Cognitive  -.031 .401 .939 
  AS Social   1.763 .323 <.001 
Note. AS = Anxiety sensitivity; anxiety= DASS-21 Anxiety; social anxiety = Social 
Phobia Inventory total; AS Physical, AS Cognitive & AS Social = three subscales of the 
ASI-3. 
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Appendix A 
 
Anxiety Sensitivity Index-3 
 
Please circle the number that best corresponds to how much you agree with each item. If 
any items concern something that you have never experienced (e.g., fainting in public) 
answer on the basis of how you think you might feel if you had such an experience. 
Otherwise, answer all items on the basis of your own experience. Be careful to circle only 
one number for each item and please answer all items. 
 Very 
Little 
A 
little 
 
Some 
 
Much 
Very 
much 
1. It is important for me not to appear 
nervous. 
0 1 2 3 4 
2. When I cannot keep my mind on a task, 
I worry that I might be going crazy. 
0 1 2 3 4 
 
3. It scares me when my heart beats 
rapidly. 
0 1 2 3 4 
4. When my stomach is upset, I worry that 
I might be seriously ill.  
0 1 2 3 4 
5. It scares me when I am unable to keep 
my mind on a task. 
0 1 2 3 4 
6. When I tremble in the presence of 
others, I fear what people might think of 
me.  
0 1 2 3 4 
 
7. When my chest feels tight, I get scared 
that I won’t be able to breathe properly.  
0 1 2 3 4 
 
8. When I feel pain in my chest, I worry 
that I am going to have a heart attack.  
0 1 2 3 4 
 
9. I worry that other people will notice my 
anxiety.  
0 1 2 3 4 
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10. When I feel “spacey” or spaced out I 
worry that I may be mentally ill.  
0 1 2 3 4 
 
11. It scares me when I blush in front of 
people.  
0 1 2 3 4 
12. When I notice my heart skipping a beat, 
I worry that there is something seriously 
wrong with me.  
0 1 2 3 4 
 
13. When I begin to sweat in a social 
situation, I fear people will think 
negatively of me.  
0 1 2 3 4 
 
14. When my thoughts seem to speed up, I 
worry that I might be going crazy.  
0 1 2 3 4 
 
15. When my throat feels tight, I worry that 
I could choke to death.  
0 1 2 3 4 
 
16. When I have trouble thinking clearly, I 
worry that there is something wrong 
with me.  
0 1 2 3 4 
 
17. I think it would be horrible for me to 
faint in public. 
0 1 2 3 4 
18. When my mind goes blank, I worry 
there is something terribly wrong with 
me.  
0 1 2 3 4 
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Appendix B 
 
Social Phobia Inventory (SPIN) 
 
Directions: Please circle the number that best corresponds to how much the statement 
applied to you over the past week. There are no right or wrong answers. Do not spend too 
much time on any one statement. 
 
Not 
at all 
A 
little 
bit 
 
Some 
what 
 
Very 
Much 
Extremely 
1. I am afraid of people in authority. 0 1 2 3 4 
2. I am bothered by blushing in front of 
people. 
0 1 2 3 
4 
 
3. Parties and social events scare me. 0 1 2 3 4 
4. I avoid talking to people I don’t 
know.  
0 1 2 3 4 
5. Being criticized scares me a lot. 0 1 2 3 4 
6. I avoid doing things or speaking to 
people for fear of embarrassment.  
0 1 2 3 4 
7. Sweating in front of people causes 
me distress.  
0 1 2 3 4 
8. I avoid going to parties.  0 1 2 3 4 
9. I avoid activities in which I am the 
center of attention.  
0 1 2 3 4 
10. Talking to strangers scares me.  0 1 2 3 4 
11. I avoid having to give speeches.  0 1 2 3 4 
12.  I would do anything to avoid being 
criticized. 
0 1 2 3 4 
13. Heart palpitations bother me when I 
am around people.  
0 1 2 3 4 
14. I am afraid of doing things when 
people might be watching.  
0 1 2 3 4 
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15. Being embarrassed or looking stupid 
are among my worst fears.  
0 1 2 3 4 
16. I avoid speaking to anyone in 
authority.  
0 1 2 3 4 
17. Trembling or shaking in front of 
others is distressing to me. 
0 1 2 3 4 
 
 
Appendix C 
DASS-21 
Anxiety Subscale 
 
Choose the number which indicates how much the statement applied to you over the past 
week.  
 
0 = Did not apply to me at all 
1 = Applied to me to some degree, or some of the time 
2 = Applied to me to a considerable degree, or a good part of the time 
3 = Applied to me very much, or most of the time 
 
________ 1. I was aware of dryness in my mouth. 
 
________ 2. I experienced breathing difficulty (e.g., excessively rapid breathing, 
    breathlessness in the absence of physical exertion). 
 
________ 3. I experienced trembling (e.g., in the hands). 
 
________ 4. I was worried about situations in which I might panic and make a fool 
of 
    myself. 
 
________ 5. I felt I was close to panic. 
 
________ 6. I was aware of the action of my heart in the absence of physical exertion 
(e.g.,  
    sense of heart rate increase, heart missing a beat). 
 
________ 7. I felt scared without any good reason. 
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Appendix D 
Medical Screening Questions 
 
1. In the last 12 months, have you experienced insomnia, difficulties falling 
asleep, or other sleeping problems (example: frequent waking)?  
☐ 
Yes  
☐No  
2. In the last 12 months, have you experienced, had difficulties with, or seen a 
medical provider for a dermatology condition or for symptoms related to skin 
problems (examples: rosacea, psoriasis, acne, eczema)?  
☐ 
Yes  
☐No  
3. In the last 12 months, have you used prescription drugs (e.g., pain pills, 
Xanax, stimulants) for non-medical purposes (examples: to get high, feel 
better)?  
☐ 
Yes  
☐No  
4. In the last 12 months, have you experienced perfect health every single day, 
all day? (examples: complete absence of: illness, ailments, 
headaches/stomachaches)  
 
☐ 
Yes  
☐No  
5. For women, are you currently pregnant or did you give birth to a 
child in the last 12 months?  
☐ N/A  
☐ 
Yes  
☐No  
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Appendix E 
Demographics Form 
 
Age: __________ 
 
Sex: ___Female  ___   Male 
 
Marital/Relationship Status: 
 
_____ (1) Single (never married, living alone, divorced, widowed, etc.) 
_____ (2) Living with a partner as if married 
_____ (3) Married BUT separated 
_____ (4) Married 
 
Ethnicity / Race:  
 
___ (1) White/Caucasian      ___ (4) Hispanic /Latino    
___ (2) Black/African American  ___ (5) Native American  
___ (3) Asian/Southeast Asian     
 
Education (the highest grade or degree you have completed): 
 
___ (1) None      ___ (6) Some College 
___ (2) 1st to 8th Grade     ___ (7) Technical or Business 
School 
___ (3) Some High School    ___ (8) College Graduate 
___ (4) High School Graduate    ___ (9) Some Graduate 
School 
___ (5) G.E.D.     ___ (10) Graduate or Professional 
Degree 
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Total Family/Household Income (Please check one): 
 
___$0 - 9,999   ___$40,000 – 49,999  ___$80,000 – 89,999 
___$10,000 – 19,999   ___$50,000 – 59,999  ___$90,000 – 99,999 
___$20,000 – 29,999  ___$60,000 – 69,999  ___$100,000 or more   
___$30,000 – 39,999   ___$70,000 – 79,999 
 
Employment Status: 
 
___ (1) unemployed       ___ (5) home-maker 
  
___ (2) employed part-time (working 1-30 hours a week)   ___ (6) part-
time student 
___ (3) employed full-time (working more than 30 hours a week)  ___ (7) retired 
___ (4) full-time student 
 
What are your current dermatological diagnoses? If unsure or no diagnosis, what 
issues, or concerns are you experiencing? (Please circle all that apply and/or describe 
current concerns) 
________________________________________________________________________
__________________ 
 
________________________________________________________________________
__________________ 
 
Acne  Birthmarks  Eczema  Herpes 
 Hidradenitis 
 
Hyperhidrosis (excessive sweating) Melasma  Psoriasis 
 Rosacea  
 
Scars  Skin Cancer  Sun Damage  Vitiligo 
 Wrinkles 
 
 
 
